Provectus Biopharmaceuticals, Inc. (PVCT)
PVCT is quoted over the counter, not listed on an exchange. Provectus Biopharmaceuticals, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | PVCT, quoted over the counter |
| SEC CIK | 0000315545 |
| OTC Markets tier | OTCQB (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Knoxville, TN |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about our ability to continue as a going concern for a period within one year after the date that the financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued." | 10-Q 2026-11-10 |
| Cash and burn | $181K cash; operating cash flow -$611K a quarter. | Report 2026-09-30 |
| Shares outstanding | 420,279,879 (2026-11-10); 420,279,879 a year earlier; 419,522,119 three years earlier. | Cover page 2026-11-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Los Angeles, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-04-16 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$1.3M | -$860K | $181K | $121K | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | Not filed | -$983K | -$358K | $1.2M | $185K | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$1.3M | -$358K | $224K | $3.0M | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $0 | -$1.2M | -$870K | $251K | $559K | $336K | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | $0 | -$1.3M | -$840K | $72K | $129K | $350K | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | $57K | -$1.8M | -$523K | $386K | $54K | $460K | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $279K | -$1.1M | -$1.1M | $390K | $125K | $658K | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $14K | -$2.4M | -$912K | $307K | $406K | $617K | 10-K 2026-03-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2017-03-06 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-07-01 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier